BioSpace News Archive

Many healthcare, pharmaceutical and biotech companies continue to place their bets on China, bringing fresh rounds of investments to and forging new partnerships with local firms.

Molecular Biology Enzymes Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Molecular Biology Enzymes market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

An influential Surgical Instrument Tracking Systems Market report provides the segmentation of the global market on the basis of technology, application, product, and region. Each segment is explained through a chapter, which has been worded with careful thought to the ever-changing market dynamics.

Eargo, Inc. announced it has completed the issuance of $100 million aggregate principal amount of senior secured convertible notes to Patient Square Capital on June 28, 2022.

Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of an aggregate of 7,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 16,500 shares of Arcutis’ common stock to three newly hired employees.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis.

MediWound Ltd. announced that it will host an in-person key opinion leader event on EscharEx for analysts and investors on Tuesday, July 12, 2022 at 8:00 am Eastern Time at the St. Regis Hotel in New York, NY.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a new non-executive employee to purchase an aggregate of 7,000 shares of common stock.

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2022 after the market close on Wednesday, July 27, 2022.

Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma (3L R and R FL).